SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of December 2012
FRESENIUS MEDICAL CARE AG & Co. KGaA
(Translation of registrants name into English)
Else-Kröner Strasse 1
61346 Bad Homburg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82
On December 10, 2012 Fresenius Medical Care AG & Co. KGaA (the Company) issued an Investor News announcing the appointment of a chief officer of global research and development (R&D) and member of its Management Board.
EXHIBITS
Exhibit 99.1 Investor News Release issued December 10, 2012.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DATE: December 10, 2012 |
|
| |
|
|
| |
|
|
| |
|
FRESENIUS MEDICAL CARE AG & Co. KGaA, | ||
|
a partnership limited by shares, represented by: | ||
|
| ||
|
FRESENIUS MEDICAL CARE MANAGEMENT AG, its | ||
|
general partner | ||
|
| ||
|
| ||
|
By: |
/s/ Dr. Ben J. Lipps | |
|
|
|
|
|
|
Name: |
Dr. Ben J. Lipps |
|
|
|
|
|
|
Title: |
Chief Executive Officer and |
|
|
|
Chairman of the Management Board |
|
|
|
of the General Partner |
|
|
|
|
|
|
|
|
|
By: |
/s/ Michael Brosnan | |
|
|
|
|
|
|
Name: |
Michael Brosnan |
|
|
|
|
|
|
Title: |
Chief Financial Officer and |
|
|
|
Member of the Management Board |
|
|
|
of the General Partner |
Exhibit 99.1
Investor News |
Oliver Maier |
|
Head of Investor Relations |
|
|
|
Fresenius Medical Care |
|
Else-Kröner-Straße 1 |
|
61352 Bad Homburg |
|
Germany |
|
T +49 6172 609-2601 |
|
F +49 6172 609-2301 |
|
oliver.maier@fmc-ag.com |
|
www.fmc-ag.com |
December 10, 2012
Fresenius Medical Care Announces Appointment of Chief Officer for Global Research and Development
Bad Homburg, Germany Fresenius Medical Care AG & Co. KGaA (the company or Fresenius Medical Care), the worlds largest provider of dialysis products and services, announced today the appointment of Dr. Olaf Schermeier (40) as chief officer of global research and development (R&D) and member of the management board. He will start in his new position on March 1st, 2013.
Dr. Schermeier has many years of experience in various areas of the health care industry. Since 2004 he has served in senior research and development positions and currently serves as president of global R&D for Draeger Medical, Lübeck, Germany. In this capacity he leads the organizations global product development for respiratory therapy, anesthesia, warming therapy, patient monitoring and clinical IT. He was also responsible for reorganizing the companys R&D efforts into one global R&D organization. Dr. Schermeier holds a doctorate degree (PhD) in Computer Science from the Technical University of Berlin, Germany and graduated from the University of Hannover, Germany in Electrical Engineering.
Rice Powell, chief executive officer of Fresenius Medical Care effective January 1, 2013, said: It is important for our future to continue to ensure market-oriented product innovations and improvements. At the same time we have to further increase the efficiency of our processes on a global basis. For this reason, we created the new role chief officer of global R&D. Olaf Schermeiers depth of global experience with Draeger Medical will provide us with some superb knowledge in this respect. We are fortunate to have a person as qualified as Olaf Schermeier and we are looking forward to working with him in this role.
Fresenius Medical Care is the worlds largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.1 million individuals worldwide. Through its network of 3,135 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 256,521 patients around the globe. Fresenius Medical Care is also the worlds leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
For more information about Fresenius Medical Care, visit the Companys website at www.fmc-ag.com.
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaAs reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.